Ongoing clinical trials with immune checkpoint inhibitors in first line setting for SCLC
| Clinical trial ID | Phase | Setting | Regimen | Endpoint |
|---|---|---|---|---|
| NCT03382561 | II | ED-SCLC | CE vs CE plus nivolumab | PFS |
| NCT02580994 (REACTION) | II | ED-SCLC | CE vs CE plus pembrolizumab | PFS |
| NCT02934503 | II | ED-SCLC | CE plus pembrolizumab +/− RT | PD-L1 changes |
| NCT03066778 (KEYNOTE-604) | III | ED-SCLC | CE plus pembrolizumab/placebo | PFSOS |
| NCT02763579 | III | ED-SCLC | CE plus atezolizumab/placebo | PFSOS |
| NCT03043872 | III | ED-SCLC | CE vs CE plus durvalumab +/−tremelimumab | PFSOS |
| NCT02402920 | I | LD-SCLC | CE-RT plus pembrolizumab | MTD |
ED-SCLC Extensive-stage Disease Small cell lung cancer, CE Cisplatin/Carboplatin plus Etoposide, PFS Progression Free Survival, DLTs Dose-limiting Toxicities, OS Overall Survival, AEs Adverse Events, ORR Overall Response Rate, LD-SCLC Limited-stage Disease Small cell lung cancer, RT Radiotherapy, MTD Maximum Tolerated Dose